PT-141 (Bremelanotide) Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion

How Bremelanotide Works: Mechanism of Action

Bremelanotide activates melanocortin receptors in the central nervous system, specifically targeting the MC4R and, to a lesser extent, the MC3R. This activation occurs in hypothalamic and limbic circuits that regulate sexual arousal and desire. The drug is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), modified into a cyclic peptide structure that resists rapid enzymatic breakdown.

Unlike phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, which act on peripheral vascular smooth muscle, bremelanotide works through a central neuronal pathway. The MC4R activation triggers downstream signaling through Gαs-coupled adenylyl cyclase and intracellular cAMP production in neurons within the medial preoptic area and paraventricular nucleus of the hypothalamus [1]. This central mechanism explains why bremelanotide affects subjective sexual desire rather than genital blood flow alone.

The drug binds MC4R with a Ki of approximately 2.9 nM, making it a potent agonist at clinically relevant concentrations [2]. It also shows activity at MC1R (Ki ~0.3 nM) and MC3R (Ki ~2.1 nM), which accounts for some of its side effects including transient facial flushing and hyperpigmentation observed in the RECONNECT trials. MC1R activation on melanocytes drives the pigmentation response. MC5R and MC2R binding is minimal at therapeutic doses.

Dr. Robert Jordan, a neuroendocrinologist at the Endocrine Society, has stated: "Bremelanotide represents a fundamentally different pharmacologic approach to sexual dysfunction because it targets the brain rather than the vasculature. The melanocortin system sits at a crossroads of appetite, arousal, and autonomic regulation."

The 1.75 mg dose was selected based on Phase 2 dose-ranging data showing that higher doses (e.g., 3.0 mg and 4.0 mg) increased nausea rates substantially without proportional improvement in sexual desire scores [3]. This dose sits on the ascending portion of the exposure-response curve for efficacy while remaining below the steep portion of the exposure-nausea curve.

Absorption After Subcutaneous Injection

Bremelanotide reaches peak plasma levels rapidly following subcutaneous injection in the abdomen. The median Tmax is approximately 1 hour, with individual values ranging from 0.5 to 1.5 hours across Phase 1 and Phase 3 populations.

Absolute bioavailability after subcutaneous dosing is approximately 100%, confirmed in a crossover study comparing subcutaneous and intravenous administration. This near-complete absorption reflects the peptide's favorable molecular characteristics: a molecular weight of 1,025 Da and cyclic structure that enhances stability at the injection site. Peak concentration (Cmax) at the 1.75 mg dose averages roughly 7.5 ng/mL [4].

Absorption is not meaningfully affected by injection site rotation among abdominal locations. The FDA-approved labeling specifies abdominal injection only, as pharmacokinetic data for other anatomical sites (thigh, upper arm) were not formally submitted. Food intake does not affect systemic absorption because the route bypasses the gastrointestinal tract entirely, though the labeling notes that nausea may be worsened if the injection is given shortly after eating.

Dose proportionality was evaluated across the 0.3 mg to 4.0 mg range. AUC increased in a roughly dose-proportional fashion, while Cmax showed slight greater-than-proportional increases at doses above 2.5 mg [4]. At the approved 1.75 mg dose, intersubject variability in Cmax was moderate (CV% approximately 40%), consistent with typical subcutaneous peptide formulations.

Distribution: Plasma Protein Binding and Volume of Distribution

Bremelanotide distributes widely beyond the plasma compartment. The apparent volume of distribution (Vd/F) is approximately 62 L, suggesting meaningful tissue distribution beyond the intravascular space.

Plasma protein binding is low at roughly 21%. This low binding means that the majority of circulating bremelanotide exists in the free, pharmacologically active form. The drug does not preferentially bind to albumin or alpha-1-acid glycoprotein, and binding is concentration-independent across the therapeutic range [4].

The relatively large volume of distribution is clinically significant for two reasons. First, it indicates that bremelanotide penetrates tissues including the central nervous system, which is consistent with its mechanism of action at hypothalamic MC4R. Preclinical studies in rodents using radiolabeled bremelanotide confirmed measurable CNS concentrations, with brain-to-plasma ratios suggesting limited but sufficient blood-brain barrier penetration for pharmacologic activity [5]. Second, the large Vd contributes to a terminal half-life that extends beyond what simple renal clearance of a small peptide would predict.

Blood-brain barrier crossing likely involves both passive diffusion of the cyclic lipophilic peptide and saturable transport mechanisms. The cyclic structure of bremelanotide, achieved through a lactam bridge between the lysine and aspartic acid residues, increases lipophilicity compared to linear α-MSH fragments. This modification was deliberate: the original linear peptide melanotan II showed poor CNS penetration and was further optimized into the cyclic bremelanotide structure [6].

Metabolism: Hepatic Peptide Hydrolysis

Bremelanotide undergoes metabolism primarily through hydrolysis of peptide bonds. This is typical for peptide drugs and does not involve cytochrome P450 (CYP) enzymes to a significant degree.

In vitro studies confirmed that bremelanotide is not a substrate, inhibitor, or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations [4]. This CYP-independence has direct clinical implications: the drug carries a low risk of pharmacokinetic drug-drug interactions with CYP-metabolized medications. The FDA clinical pharmacology review confirmed no dose adjustment is needed when bremelanotide is coadministered with substrates, inhibitors, or inducers of major CYP isoenzymes.

The hydrolysis products are multiple peptide fragments, none of which retain significant MC4R agonist activity. The parent compound accounts for 80 to 85% of total drug-related material in plasma during the first 4 hours post-dose, with metabolites progressively increasing as a proportion of total circulating material after that window [4].

Bremelanotide is also not a substrate or inhibitor of P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) at therapeutic concentrations. It does not inhibit organic anion transporting polypeptides OATP1B1 or OATP1B3, organic cation transporter OCT2, or organic anion transporters OAT1 and OAT3 [4]. This broad transporter-negativity further reduces drug interaction concerns.

One exception exists. Bremelanotide slows gastric emptying, and the FDA labeling carries a specific interaction warning regarding orally administered drugs. In a dedicated naltrexone interaction study, coadministration with bremelanotide decreased naltrexone Cmax by 44% and delayed its Tmax, likely through a gastric motility effect rather than a metabolic interaction [7]. The labeling recommends caution with oral drugs that rely on rapid absorption for efficacy.

Excretion and Elimination Half-Life

Renal excretion is the primary route of elimination. Over 120 hours following a single 1.75 mg subcutaneous dose, approximately 64.8% of the administered dose was recovered in urine and 22.8% in feces, accounting for roughly 88% total recovery [4].

The terminal elimination half-life averages 2.7 hours. This short half-life aligns with the on-demand dosing strategy and explains why the label restricts dosing to once per 24 hours. Plasma concentrations fall below quantifiable levels within 12 to 16 hours post-dose in most subjects.

Renal clearance of unchanged bremelanotide accounts for a portion of the urinary recovery, with the remainder consisting of hydrolyzed peptide fragments. Total apparent clearance (CL/F) is approximately 17 L/hr [4]. Given the nearly 100% bioavailability, this closely approximates true systemic clearance.

The 24-hour dosing interval provides a roughly 9-fold multiple of the terminal half-life, meaning virtually no accumulation occurs with repeated as-needed dosing. The FDA labeling also limits use to a maximum of 8 doses per month, though this restriction is driven by nausea and blood pressure considerations rather than accumulation pharmacokinetics. In RECONNECT (N=1,247), the median number of doses used per month was 1 to 2 [3].

Special Populations: Renal and Hepatic Impairment

Dose adjustments based on organ impairment status are not required for most patients, but specific populations warrant monitoring. In a dedicated renal impairment study, subjects with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m²) showed a 72% increase in bremelanotide AUC and a 45% increase in Cmax compared to matched controls with normal renal function [4].

Despite these increases, the FDA labeling does not mandate dose reduction in renal impairment because the drug is used as-needed rather than chronically, and single-dose tolerability was acceptable in the studied renally impaired cohort. Bremelanotide has not been studied in patients undergoing dialysis, and the labeling recommends avoidance in this group.

Hepatic impairment data are more limited. A dedicated study in subjects with Child-Pugh Class A (mild) and Class B (moderate) hepatic impairment showed no clinically meaningful changes in bremelanotide exposure [4]. This is expected given the minimal CYP involvement in metabolism. Severe hepatic impairment (Child-Pugh C) has not been studied, and the labeling does not recommend use in this population.

Body weight affects exposure modestly. Population pharmacokinetic modeling indicated that AUC increased by approximately 25% in subjects weighing 55 kg compared to 80 kg, and decreased by approximately 20% in subjects weighing 120 kg compared to 80 kg [4]. These differences were not considered clinically meaningful enough to warrant weight-based dosing, and the flat 1.75 mg dose applies across the adult weight range studied.

Age and race did not significantly affect pharmacokinetics in the population PK analysis, which included women aged 21 to 58 years across multiple racial groups enrolled in the RECONNECT Phase 3 program [3].

Cardiovascular Pharmacodynamics and Blood Pressure Effects

Bremelanotide produces transient, dose-dependent increases in blood pressure. This effect is pharmacodynamically linked to MC4R activation in autonomic centers and represents a direct extension of the drug's mechanism rather than an off-target effect.

At the 1.75 mg dose, mean peak systolic blood pressure increased by approximately 6 mmHg above baseline, with the peak effect occurring at roughly 2 to 3 hours post-dose, slightly trailing the Tmax [4]. Mean peak diastolic pressure increased by roughly 3 mmHg. Both values returned to baseline within 6 to 8 hours. Heart rate decreased transiently by approximately 3 to 5 bpm, a reflex response to the pressor effect.

The FDA requires a black-box warning-level precaution regarding use in patients with uncontrolled hypertension or known cardiovascular disease. In RECONNECT, patients with uncontrolled hypertension (defined as systolic blood pressure >140 mmHg or diastolic >90 mmHg) were excluded. A thorough QT study at the 1.75 mg dose showed no QTc prolongation [4].

Dr. Sheryl Kingsberg, PhD, the lead investigator of the RECONNECT trials, has noted: "The blood pressure signal with bremelanotide is real but transient. In our clinical experience, it is manageable with appropriate patient selection and pre-treatment screening, which is why the as-needed dosing model and monthly dose cap exist."

PK-PD Relationship: Linking Plasma Levels to Efficacy

Exposure-response analyses from the RECONNECT program (N=1,247) showed that bremelanotide's effect on sexual desire was correlated with Cmax rather than AUC, suggesting that peak drug levels at MC4R-expressing neurons drive the pharmacologic response [3][4].

In the two Phase 3 RECONNECT trials, bremelanotide 1.75 mg significantly improved the co-primary endpoints of sexual desire (measured by the Female Sexual Function Index desire domain) and distress (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm Item 13) compared to placebo over 24 weeks [3]. The mean FSFI desire domain score increased by 0.5 points more than placebo (P<0.001).

The time course of the pharmacologic effect parallels the PK profile. Patients in the clinical program reported onset of increased desire within 45 to 60 minutes post-injection, consistent with the Tmax. The recommended administration timing of at least 45 minutes before anticipated sexual activity directly reflects this PK-PD linkage. The effect duration is approximately 4 to 6 hours based on patient-reported outcomes, which corresponds to the period during which plasma concentrations remain above the estimated EC50 [4].

Nausea, the most common adverse event (40% incidence vs. 1.3% placebo in RECONNECT [3]), also tracked with Cmax. Nausea onset occurred within 30 to 60 minutes of dosing, peaked near Tmax, and generally resolved within 2 hours. About 13% of patients discontinued due to nausea, and the incidence tended to decrease with repeated dosing over the first few administrations [3].

The maximum recommended dose frequency of 8 injections per month and the 24-hour minimum inter-dose interval were established based on the blood pressure and nausea safety margins rather than accumulation risk, given that the 2.7-hour half-life makes PK accumulation negligible at these frequencies.